At Revalesio we are using a novel technology to develop safe treatments for grievous illnesses with an unmet clinical need.
Our technology initially demonstrated a significant yield increase in vegetable producing plants grown in hydroponic systems with a simultaneous reduction in disease burden.
This prompted the question about a possible impact on human biology.
Conducting a wide-ranging and intensive discovery effort, we observed significant biological effects. Physiological fluids processed with our technology have anti-inflammatory properties and exert a positive impact on mitochondria and bioenergetics, thereby protecting cells exposed to stressful conditions.
Based on an extensive pre-clinical research program as well as FDA-approved human safety studies, we are now aggressively pursuing clinical proof-of-concept studies in Asthma, Multiple Sclerosis, Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS), and Endometriosis.
We have been working with leading partners in academic research and commercial development around the globe, which allows us to gain a deeper understanding of our technology and rapidly advance our lead therapeutic candidate into human studies.
Together, we are developing the commercial applications of our technology as therapeutics for a wide range of unmet medical needs.